The IFN-stimulated gene ubiquitin-specific proteinase 18 (USP18) encodes a protein that nega- 
INTRODUCTION
It is well established that type I IFNs (T1 IFNs) can restrict acute HIV-1 infection in vitro. [1] [2] [3] [4] [5] In clinical trials treating human patients with recombinant IFN-2a, T1 IFNs can suppress viral replication in the absence of antiretroviral therapy (ART) in some patients. 6, 7 However, this approach failed in long-term treatment when study subjects became refractory to IFN treatment and viral loads returned to previous levels. T1 IFNs are important in establishing early control of HIV-1 in an in vivo SIV rhesus macaque model, 8 but chronic T1 IFN signaling Abbreviations: ART, antiretroviral therapy; Cas9, CRISPR-associated protein 9; CRISPR, clustered regularly interspaced short palindromic repeats; HIV-1, Human immunodeficiency virus 1; IFNAR, IFN-receptor; iMacs, iPSC-derived macrophages; iPSC, induced pluripotent stem cells; IRF, IFN regulatory factor; ISG, IFN-stimulated gene; LCMV, lymphocytic choriomeningitis virus; MDM, monocyte-derived macrophage; T1 IFN, type I IFN; USP18, ubiquitin-specific proteinase 18. correlates with chronic immune activation, immune exhaustion, elevated IFN-stimulated gene (ISG) expression, and poor long-term control of HIV-1. 9, 10 Two recently published studies have shown that in a humanized mouse model of HIV-1 infection that experimental blockade of T1 IFN signaling resulted in restored immune function and rescued T cell function, including HIV-1-specific T cells. 11, 12 In chronic lymphocytic choriomeningitis virus (LCMV) infection, blockade of IFN-receptor (IFNAR) also had significant benefit. 13, 14 These studies highlight the importance of IFN regulation in the context of HIV-1 infection specifically and viral infections in general. However, little is known about how HIV-1 induces IFNs and why IFNs are unable to control infection in vivo.
Signaling through IFNAR results in the phosphorylation and activation of STAT proteins including STAT1 and STAT2. The consequence of STAT1/2 phosphorylation is induced expression of hundreds of ISGs. [15] [16] [17] The protein products of ISGs then target host and viral machinery as a means to restrict viral replication. However, a small subset of the ISGs expressed are negative feedback mechanisms that turn off IFN signaling so that resolution of the immune response can occur.
One of these important negative regulators is ubiquitin-specific proteinase 18 (USP18).
USP18 is an IFN-inducible deISGylating enzyme that specifically removes the ubiquitin-like posttranslational modification, ISG15, from target proteins. [18] [19] [20] During an IFN response, many newly synthesized proteins are ISGylated, 21 which can have a variety of effects depending on the target. Some targets, such as IFN regulatory factor 3 (IRF3), are protected from ubiquitin-mediated proteasomal degradation. 22 It has also been shown that viral proteins, including HIV-1 Gag, can be ISGylated. 23 Durfee and colleagues 21 propose that during an infection a small subset of viral structural proteins are ISGylated to disrupt the repeating structures found in viral capsids. Influenza B has evolved a mechanism to directly neutralize ISG15 with its NS1 protein 24 and coronaviruses have a papain-like protease that has deISGylase activity as a strategy to overcome ISG15, 25, 26 indicating the importance of ISG15 in the antiviral response.
In addition to its enzymatic activity, USP18 negatively regulates T1 IFN signaling. 27 USP18 is recruited by STAT2 to the type I IFN receptor subunit, IFNAR2, where it binds to IFNAR2 and prevents phosphorylation of JAK1 by blocking the interaction of JAK1 and the IFNAR2 subunit. [27] [28] [29] USP18 expression also plays a role in limiting TRAILinduced apoptosis and has also been shown to regulate the susceptibility of certain cancer cells to IFN-and drug-induced apoptosis. 30, 31 Macrophages play an important role in HIV-1 as reservoirs and can contribute directly to HIV-1 pathogenesis. 32 HIV-1 in the ART era can be seen as a chronic disease characterized by chronic immune activation and chronic inflammation with a higher risk of non-AIDS-related morbidities and mortalities. Macrophages play an important role in this process and can act as mediators of inflammation. 33, 34 We recently reported that HIV-1 replication in macrophages requires activity of STAT1, a protein usually associated with antiviral responses. 35 The role of STAT1 was in postintegration expression of HIV-1 mRNA from the long terminal repeat (LTR) promoter. This paradoxical mechanism where HIV-1 usurps antiviral pathways as a means of driving its own replication suggests that a complex host-pathogen interplay ultimately determines if HIV-1 can efficiently replicate in macrophages. In general, the role of macrophages in the HIV-1 life cycle is important because eliminating persistently infected macrophages in addition to latently infected T cells will be necessary for a sterilizing cure to be achieved. Thus, it is critical that we understand the host-pathogen dynamics that regulate HIV-1 replication in macrophages and understand how HIV-1 subverts the innate immune response including the potent antiviral T1 IFN response.
Our data show that USP18 expression is induced by HIV-1 in human macrophages. The goal of this study was to determine the role of USP18 in HIV-1 infection/replication and determine if the IFNAR-blocking effect of USP18 benefits HIV-1. We hypothesized that USP18 suppresses antiviral pathways that would normally restrict HIV-1 and that perturbing USP18 would restore and enhance these pathways leading to better control of the virus. Triangle Park, NC), 2 mM L-glutamine (Corning), and 100 IU penicillinstreptomycin (Corning)) supplemented with 10 ng/mL M-CSF for 7-10 days. After differentiation, the medium was replenished without M-CSF and the cells rested overnight before being used for experiments. 41, 42 were cultured and maintained in RPMI 1640 with 2 mM L-glutamine (Corning), 10% heat-inactivated FBS (Sigma-Aldrich), 100 IU penicillin-streptomycin (Corning), and 10 mM HEPES (Corning). 
THP-1 cells

Cytokines and antibodies
HIV-1 virus production
Lenti-X 293T cells were cultured in a T75 flask and transfected with pNL4-3-Bal-IRES-HSA using the Viromer R Red transfection reagent (Lipocalyx, Halle, Sachsen-Anhalt, Germany) or pNL(AD8) using the 
TZM-bl cell luciferase assays
Medium was removed by aspiration and 100 L of room temperature 
Microarrays
Monocyte-derived macrophages (MDMs) were infected with 500 TCID 50 imported with GC correction and intensity data were transformed to log base 2. Exons were summarized to genes using the median method and an ANOVA with contrast was performed to determine fold changes between control and treatment groups.
Microarray data have been deposited at Gene Expression Omnibus (accession# GSE108897). Blots were stripped by incubating with Restore TM PLUS Western Blot Stripping Buffer (Thermo Scientific).
Western blotting
shRNA lentivirus
Human GIPZ lentiviral shRNA gene set for USP18-specific shRNA were purchased from GE Dharmacon (Lafayette, CO). The shRNA clones were screened in HEK 293 cells and clone V3LHS_645758
(USP18-5) was determined to most efficiently knockdown USP18 (data not shown) and was used for all subsequent experiments. GIPZ plasmid DNA was cotransfected into Lenti-X 293T packaging cells cultured in 293T medium with Tet System approved FBS (tetracycline-free) using the Lenti-X HTX Packaging System (Clontech) and Xfect Transfection Reagent (Clontech) according to the manufacturer's instructions.
The transfection reagent was removed 24 h posttransfection. After 48 h, supernatants containing VSV-G pseudotyped lentivirus were harvested and clarified by centrifugation at 20,000 x g for 18 h.
The supernatant was decanted and the pellet was resuspended in THP-1 medium. THP-1 cells were transduced with TransDux (System Biosciences, Mountain View, CA) by spinoculation for 1 hour at 1200 x g at room temperature. Puromycin (1 g/ml) was used to select for transduced cells 48 h posttransduction.
siRNA transfections
ON-TARGETplus Non-targeting Pool control siRNA (D-001810-10-05) and ON-TARGETplus USP18 siRNA SMARTpool (L-004236-00-0005)
were purchased from GE Dharmacon. siRNA was transfected into cells with Viromer R Blue transfection reagent (Lipocalyx) at a concentration of 25 nM according to the manufacturer's instructions.
RT-qPCR
Total RNA was isolated with RNeasy Plus Mini Kit (Qiagen). cDNA 
Reprogramming CD34 + to iPSCs
Differentiation of iPSCs to monocytes
Differentiation was carried out as previously described 48 
iPSC USP18 gene knockout using CRISPR/Cas9
iPSCs were transfected using the Human Stem Cell Nucleofector Kit Table S1 . 
DQ-Ovalbumin and phagocytosis assays
Flow cytometry
Fc receptors were blocked with Fc Block (Miltenyi) and stained with antibodies in PBS with 1% human serum. For intracellular staining of CD68, the cells were fixed and permeabilized with the BD Cytofix/Cytoperm TM kit (BD Biosciences). All samples were analyzed with the BD Accuri TM C6 Cytometer (BD Biosciences).
Integration assay
The integration assay for detection of integrated HIV-1 proviral DNA was adapted from methods previously described. 49 Primer sequences are listed in Supplemental Table S1 . Using an estimate of ∼6.6 pg of genomic DNA per cell, the number of copies of integrated proviral genomes per 10,000 cells was calculated from the standard curve.
RESULTS
T1 IFNs restrict HIV-1 replication
It has been demonstrated previously in vitro that T1 IFNs restrict HIV-1 replication. [1] [2] [3] [4] [5] 51 To confirm these previous findings, we pretreated TZM-bl cells with different doses of IFN-for 24 h and infected the cells with HIV-1. As previously reported, T1 IFN restricted HIV-1 replication in a dose-dependent manner (Fig. 1A) . We also tested this in MDMs and found that HIV-1 replication is potently restricted by IFN-in a dose-dependent manner (Fig. 1B) with an IC 50 of 504.7 fg/mL (± 142.1 fg/mL).
USP18 is induced by HIV-1 in MDMs and requires T1 IFN activity
Since HIV-1 is restricted by T1 IFNs in vitro, we wanted to determine if HIV-1 was inducing an IFN response in MDMs. To test this, MDMs were infected with HIV-1 for 7 days and gene expression was analyzed by microarray ( Fig. 2A) . We observed that all genes up-regulated at least 2-fold by HIV-1 (Table 1) have been reported to be IFN-inducible in the Interferome (v2.01) database (Fig. 2B) . However, this IFN-like response is not strong enough to inhibit HIV-1 replication to the same degree as the addition of exogenous IFN (Fig. 1 ). We were interested in how the IFN response was being attenuated and allowing for signaling. 27 Western blot analysis confirmed this at the protein level with 2 different strains of HIV-1 (Fig. 2C) .
It is unknown how HIV-1 induces USP18 expression in human macrophages. Since USP18 is an ISG, we first pretreated MDMs with -IFNAR neutralizing antibodies then infected the cells to see if USP18
was still induced by HIV-1 in the absence of T1 IFN signaling. The results show that USP18 is not induced by HIV-1 in the absence of T1 IFN signaling (Fig. 3) , providing evidence that HIV-1 does induce an IFN response in macrophages that has an autocrine effect.
Surprisingly, HIV-1 replication was inhibited, not enhanced, in the absence of T1 IFN signaling as measured by Gag p24 ELISA on supernatants (Fig. 3) . This finding agrees with previous work where we demonstrated the importance of STAT signaling for HIV-1 replication in MDMs. 35 These data demonstrate that HIV-1 must strike a balance between some T1 IFN signaling, which is needed for producing transcription factors such as STAT1 and STAT3, and too much IFN signaling, which allows the cells to mount an effective antiviral response. Given that USP18 attenuates the IFN response, we hypothesized that induction of USP18 allowed HIV-1 to achieve the balance needed to provide the necessary STAT signaling, without too strong an antiviral response.
USP18 deficiency enhances IFN signaling through JAK-STAT pathway
USP18 is part of the normal negative feedback response that regulates T1 IFN signaling through IFNAR and JAK-STAT signaling. In the absence of USP18, signaling through the JAK-STAT pathway should be enhanced with increased levels of phosphorylated STAT1 and STAT2.
We used siRNA to knockdown USP18 expression in MDMs and treated them with IFN-for 18 hours and found increased levels of phosphorylated STAT1 and STAT2 (Fig. 4A ). genes had increased expression when USP18 was knocked down compared with control (Fig. 4B ). USP18 expression was also measured to confirm knockdown of USP18 transcripts.
USP18 knockdown restricts HIV-1 replication
We next wanted to determine if USP18 expression is necessary for HIV-1 replication. Although transfecting MDMs with siRNA allowed for efficient knockdown of USP18 (Fig. 4) , it also made the cells refractory to infection even with a nontargeting control siRNA (data not shown). Instead, we utilized shRNA knockdown of USP18 in the THP-1 cell line. THP-1 cells are suspension cells that can be differentiated into adherent macrophage-like cells with PMA treatment. They are a well-established model system for studying HIV-1 infection in macrophages. 52 We generated THP-1 cell lines that constitutively express nontargeting control or USP18-specific shRNA (Supplemental Figs. S1A and S1B). After PMA differentiation, THP-1 cells expressing non-targeting control or USP18 shRNA were infected by HIV-1. We found that HIV-1 replication was significantly restricted in THP-1 cells with USP18 knockdown. There was significantly less Gag p24 detected in the supernatants and in the protein lysates of USP18 knockdown cells compared with control (Figs. 5A and 5B).
iPSC-derived macrophages
While THP-1 cells and MDMs with USP18 knockdown provide useful models for investigating the effects of USP18 deficiency on IFN signaling, it may not be the best model. THP-1 cells are transformed cells with an abnormal karyotype 53 and in our hands they do not remain differentiated and adherent in culture for more than 5 days (data not shown). S3C ). To determine if iMacs can phagocytose whole bacteria and process them in acidified phagosomes, heat killed E. coli and S. aureus labeled with a pH sensitive dye were fed to iMacs.
After 2 h, the iMacs were RFP positive indicating that they phagocytosed the bacteria and that the phagosomes were acidified (Supplemental Fig. S3C ).
CRISPR knockout of USP18 in iMacs
To test the effects of USP18 deficiency in iMacs, we utilized CRISPR/Cas9 gene editing to knockout USP18 in iPSCs before differentiation to the myeloid lineage. The advantage of knocking out USP18 in iPSCs is that once knockout is achieved, we have a selfrenewing iPSC line that can be a continuous source of new EBs for making iMacs. To knockout USP18, iPSCs were transfected with 3 plasmids that delivered a USP18 targeting single-guide RNA (sgRNA), Cas9, and a donor plasmid with homology arms to the region where the sgRNA targets USP18 in exon 2 (Fig. 6A) . The donor DNA contains a GFP and puromycin resistance gene allowing for selection of successfully modified cells. Puromycin resistant clones were screened by PCR and were measured by Western blot. USP18 −/− iMacs had increased and sustained phosphorylated STAT1 and phosphorylated STAT2 (Fig. 7A ).
Since USP18 −/− iMacs also had increased STAT1 and STAT2 signaling, we wanted to determine if USP18 −/− iMacs also had enhanced ISG expression after IFN-treatment. Indeed, after treatment with IFNfor 18 h, USP18 −/− iMacs had increased expression of ISGs compared with USP18 sufficient cells (Fig. 7B) . These findings are consistent with the results from siRNA knockdown in MDMs.
HIV-1 replication is restricted in USP18 knockout iMacs
We next determined if iMacs can support HIV-1 replication as previously reported 48 and if USP18 is induced by HIV-1 in iMacs. Indeed, USP18 +/+ iMacs support HIV-1 replication and USP18 is induced by HIV-1 in these cells (Figs. 8A and 8B ). Since USP18 is induced by HIV-1 in iMacs in a similar manner as MDMs, we concluded that iMacs are a better model for studying USP18 knockout/knockdown than THP-1 cells.
Next, we wanted to determine if USP18 knockout influenced HIV-1 replication. USP18 knockout results in an enhanced response to IFN stimulation in macrophages (Fig. 7) . Therefore, we hypothesized that HIV-1 replication would be restricted in USP18 −/− iMacs due to enhanced IFN signaling in response to infection. iMacs were infected with HIV-1 and there was a significant reduction in supernatant Gag p24 and intracellular Gag p24 as determined by ELISA and
Western blot in USP18 −/− iMacs at days 4 and 8 postinfection (Figs. 8C and 8D ).
We also wanted to determine if the restriction in HIV-1 replication was due to fewer cells becoming infected during the first round of infection or if it was due to decreased spreading. To test this, iMacs were infected and treated with Darunavir, an HIV-1 protease inhibitor, to prevent subsequent rounds of infection. After 24 h, genomic DNA was collected and a qPCR assay developed to measure integrated proviral genomes showed that there were on average 3800 genomes per 10,000 cells in USP18 +/+ iMacs and on average 4900 
DISCUSSION
We report here that USP18 deficiency restricts HIV-1 replication in human macrophages using an iPSC model. The restriction on replication was due to an enhanced IFN response from a lack of feedback inhibition on the JAK/STAT pathway resulting in increased expression of ISGs that have antiviral effects. Previous work done by our group has shown that STAT1 and STAT3 are necessary for efficient HIV-1 replication. Blocking phosphorylation of either of these 2 molecules resulted in significant reduction in viral replication. 35 However, the current study shows that increasing the amount of phosphorylated STAT1 and STAT2 also results in a significant reduction in viral replication. Thus, we propose that USP18 acts as a tuning mechanism which prevents a robust IFN response that would restrict viral replication (Fig. 9) . Previous work has shown that Usp18 −/− mice exhibit protection from intracerebral infection by LCMV and VSV. 55 Usp18 −/− mice also The basis of antibacterial protection in USP18 deficiency can be attributed to hypersensitivity to LPS as a consequence of an overactive T1 IFN response. 56 Mechanistically, these studies showed that USP18 deficiency resulted in increased ISGylation of proteins and increased phosphorylated STAT1 levels in response to LPS treatment or viral infection. It was based on these properties that we sought to determine if human USP18 regulates HIV-1 replication.
Differences in biochemical regulation of USP18 in humans compared with mice provide rationale to study USP18 deficiency in human Similar to mouse studies, our current work shows that USP18 deficient human macrophages also have enhanced levels of phosphory- proteins. 67 The IFITM family members have been shown to inhibit HIV-1, by interfering with viral fusion or binding. [68] [69] [70] This could potentially result in fewer cells being infected. MX2 is another IFNinducible factor that has been shown to restrict HIV-1 replication. 71, 72 The effects of these ISGs may simply be enhanced in the absence of 
